肥胖药品价格下降,但高昂的费用和不均衡的保险范围限制了许多人获得药物的机会。 Obesity drug prices drop, but high costs and uneven insurance coverage limit access for many.

尽管肥胖症药品的价格下跌,但获得治疗仍很困难。 Despite price drops for obesity drugs Wegovy and Zepbound, access remains challenging. 没有保险者每月的费用仍可达500美元,保险范围不均匀,医疗保险和大多数医疗补助方案不覆盖这些治疗。 Monthly costs can still reach $500 for the uninsured, and coverage is uneven, with Medicare and most Medicaid programs not covering these treatments. 一些雇主和药店福利管理人员由于成本而降低了保险覆盖率,而药品制造商正在研制药片,以进一步降低价格。 Some employers and pharmacy benefit managers have dropped coverage due to costs, while drugmakers are developing pill versions that could further reduce prices.